Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Aug;26(2):143–154. doi: 10.1111/j.1365-2125.1988.tb03380.x

Acute and long-term renal and metabolic effects of piretanide in congestive cardiac failure.

W R McNabb 1, F H Noormohamed 1, A F Lant 1
PMCID: PMC1386521  PMID: 3207551

Abstract

1. The renal and metabolic effects of the sulphamoylbenzoic acid diuretic, piretanide, have been studied, under controlled dietary conditions, in 39 patients with congestive cardiac failure. 2. In acute studies, peak saluresis occurred within 4 h of oral piretanide administration; saluresis was complete within 6 h, after which a significant antidiuretic effect was observed. Addition of triamterene, 50 mg, blunted the 0-6 h kaliuretic effect of piretanide. Over 24 h, piretanide, alone, caused insignificant urinary losses of potassium when compared with control. 3. In comparative studies, the piretanide dose-response curve was found to be parallel to that of frusemide over the dose range studied. The 0-6 h saluretic responses of piretanide, 6, 12 and 18 mg, were found to be equivalent to frusemide, 40, 80 and 120 mg respectively. The collective mean ratios of all the saluretic responses to each dose of piretanide with the corresponding dose of frusemide was observed to be 0.99 +/- 0.12, over 0-6 h period, and 0.86 +/- 0.09 over the 24 h period. The relative potency of piretanide, when compared with frusemide was found to be 6.18 (95% confidence limits 4.87-8.33), over the 0-6 h period, and 4.73 (95% confidence limits 3.65-6.14), over 24 h period. 4. In 15 patients in severe cardiac failure, urinary recovery of piretanide, over first 6 h, at the start of treatment was 21.2 +/- 2.1% while efficiency of the diuretic (mmol Na/mg drug) was 47.3 +/- 4.1. Long-term piretanide therapy was continued in the same group for up to and in some cases over 3 years. No other diuretics or potassium supplements were given. Piretanide dosage ranged from 6 to 24 mg day-1 according to clinical need. Plasma potassium fell significantly at 12 and 24 months, though remaining within the normal range. At these same times, significant elevations in both plasma urate and total fasting cholesterol were observed. Two patients developed overt gout on high dose piretanide therapy (24 mg day-1). Piretanide was well tolerated, and effective in the management of congestive cardiac failure without any other recognized metabolic or electrolyte changes.

Full text

PDF
143

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ames R. P., Hill P. Elevation of serum lipid levels during diuretic therapy of hypertension. Am J Med. 1976 Nov;61(5):748–757. doi: 10.1016/0002-9343(76)90156-x. [DOI] [PubMed] [Google Scholar]
  2. Anderson J., Godfrey B. E., Hill D. M., Munro-Faure A. D., Sheldon J. A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. Q J Med. 1971 Oct;40(160):541–560. [PubMed] [Google Scholar]
  3. Bailie G. R., Grennan A., Waldek S. Bioavailability of bumetanide in grossly oedematous patients. Clin Pharmacokinet. 1987 Jun;12(6):440–443. doi: 10.2165/00003088-198712060-00004. [DOI] [PubMed] [Google Scholar]
  4. Buckert C., Muhlhausler W., Fratzer U., Verho M. A double-blind multicentre study of piretanide and hydrochlorothiazide in patients with essential hypertension. J Int Med Res. 1984;12(2):81–86. doi: 10.1177/030006058401200203. [DOI] [PubMed] [Google Scholar]
  5. Cleland J. G., Dargie H. J., Robertson I., Robertson J. I., East B. W. Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension. Br Heart J. 1987 Sep;58(3):230–238. doi: 10.1136/hrt.58.3.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clissold S. P., Brogden R. N. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1985 Jun;29(6):489–530. doi: 10.2165/00003495-198529060-00002. [DOI] [PubMed] [Google Scholar]
  7. Dixey J. J., Noormohamed F. H., Lant A. F., Brewerton D. A. The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man. Br J Clin Pharmacol. 1987 Jan;23(1):55–63. doi: 10.1111/j.1365-2125.1987.tb03009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gabriel R., Baylor P. Comparison of the chronic effects of bendrofluazide, bumetanide and frusemide on plasma biochemical variables. Postgrad Med J. 1981 Feb;57(664):71–74. doi: 10.1136/pgmj.57.664.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Glück Z., Baumgartner G., Weidmann P., Peheim E., Bachmann C., Mordasini R., Flammer J., Keusch G. Increased ratio between serum beta- and alpha-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med Suppl. 1978 Dec;4:325s–328s. doi: 10.1042/cs055325s. [DOI] [PubMed] [Google Scholar]
  10. Greenberg G., Brennan P. J., Miall W. E. Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial. Am J Med. 1984 Feb 27;76(2A):45–51. doi: 10.1016/0002-9343(84)90956-2. [DOI] [PubMed] [Google Scholar]
  11. Harrington J. T., Isner J. M., Kassirer J. P. Our national obsession with potassium. Am J Med. 1982 Aug;73(2):155–159. doi: 10.1016/0002-9343(82)90171-1. [DOI] [PubMed] [Google Scholar]
  12. Langford H. G., Blaufox M. D., Borhani N. O., Curb J. D., Molteni A., Schneider K. A., Pressel S. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med. 1987 Apr;147(4):645–649. doi: 10.1001/archinte.147.4.645. [DOI] [PubMed] [Google Scholar]
  13. Lant A. F., Smith A. J., Wilson G. M. Clinical evaluation of amiloride, a potassium-sparing diuretic. Clin Pharmacol Ther. 1969 Jan-Feb;10(1):50–63. doi: 10.1002/cpt196910150. [DOI] [PubMed] [Google Scholar]
  14. Lant A. Diuretics. Clinical pharmacology and therapeutic use (Part I). Drugs. 1985 Jan;29(1):57–87. doi: 10.2165/00003495-198529010-00003. [DOI] [PubMed] [Google Scholar]
  15. Lasser N. L., Grandits G., Caggiula A. W., Cutler J. A., Grimm R. H., Jr, Kuller L. H., Sherwin R. W., Stamler J. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984 Feb 27;76(2A):52–66. doi: 10.1016/0002-9343(84)90957-4. [DOI] [PubMed] [Google Scholar]
  16. Lawrence J. R., Ansari A. F., Elliott H. L., Sumner D. J., Brunton G. F., Whiting B., Whitesmith R. Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther. 1978 May;23(5):558–565. doi: 10.1002/cpt1978235558. [DOI] [PubMed] [Google Scholar]
  17. Losse H., Zumkley H., Quante T. Side effects of diuretics. Clin Exp Hypertens A. 1983;5(2):309–320. doi: 10.3109/10641968309048829. [DOI] [PubMed] [Google Scholar]
  18. McNabb W. R., Noormohamed F. H., Brooks B. A., Lant A. F. Renal actions of piretanide and three other "loop" diuretics. Clin Pharmacol Ther. 1984 Mar;35(3):328–337. doi: 10.1038/clpt.1984.38. [DOI] [PubMed] [Google Scholar]
  19. Morgan D. B., Burkinshaw L., Davidson C. Potassium depletion in heart failure and its relation to long-term treatment with diuretics: a review of the literature. Postgrad Med J. 1978 Feb;54(628):72–79. doi: 10.1136/pgmj.54.628.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Roberts C. J., Homeida M., Roberts F., Bogie W. Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects. Br J Clin Pharmacol. 1978 Aug;6(2):129–133. doi: 10.1111/j.1365-2125.1978.tb00837.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sherman L. G., Liang C. S., Baumgardner S., Charuzi Y., Chardo F., Kim C. S. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986 Nov;40(5):587–594. doi: 10.1038/clpt.1986.228. [DOI] [PubMed] [Google Scholar]
  22. Skorecki K. L., Brenner B. M. Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med. 1982 Feb;72(2):323–338. doi: 10.1016/0002-9343(82)90824-5. [DOI] [PubMed] [Google Scholar]
  23. Steele T. H. Evidence for altered renal urate reabsorption during changes in volume of the extracellular fluid. J Lab Clin Med. 1969 Aug;74(2):288–299. [PubMed] [Google Scholar]
  24. Vasko M. R., Cartwright D. B., Knochel J. P., Nixon J. V., Brater D. C. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985 Mar;102(3):314–318. doi: 10.7326/0003-4819-102-3-314. [DOI] [PubMed] [Google Scholar]
  25. Verho M., Rangoonwala B., Dols W., Fratzer U., Kaczynski J., Mühlhäusler W. Piretanide, a potassium stable diuretic, in the treatment of essential hypertension. Eur J Clin Pharmacol. 1984;27(4):407–414. doi: 10.1007/BF00549586. [DOI] [PubMed] [Google Scholar]
  26. Välimäki M., Harno K., Nikkilä E. A. Serum lipoproteins and indices of glucose tolerance during diuretic therapy: a comparison between hydrochlorothiazide and piretanide. J Cardiovasc Pharmacol. 1983 Jul-Aug;5(4):525–530. doi: 10.1097/00005344-198307000-00003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES